课题基金 / 基金详情

项目摘要

项目成果

Shirley Wang的其他基金

相似基金

相关文献

中文摘要
翻译
老年人在随机对照试验中的代表性往往很低,甚至被排除在外。 (随机对照试验)导致FDA批准新药,但对于许多药物来说,它们代表了大多数患者 批准后在常规护理中接受药物治疗的。药物在试验中被证明有一定的结果 年轻人群在老年人中可能没有类似的效果,这种使用也可能使患者 未充分代表年龄较大的群体,出现意外副作用的风险增加。目前的R01拨款 (《了解新药在进入市场后不久在老年人中的有效性》)评估了一个框架 对FDA批准的新药在老年患者中的有效性进行更及时和更有力的洞察 成年人。这项补充申请增加了R01拨款,其中包括生物伦理学研究 当RCT导致FDA批准时,为老年患者开药的问题不包括 那些病人。 我们将探索在不同人群中使用药物的生物伦理影响 招募到其关键的区域协调小组,包括需要加强披露,作为知情同意的一部分 程序和监管改革,使批准以真实产生的证据为条件- 世界患者群体。这些目标将通过对老年患者进行焦点小组来实现 以及对处方者的半结构化访谈。根据这些研究工作的结果,我们将 制定监管和临床实践建议,以促进患者的自主权和知情 做决定。
英文摘要
Older adults are often underrepresented in or even excluded from the randomized controlled trials (RCTs) leading to FDA approval of new drugs, but for many drugs they then represent the majority of patients receiving the drug in routine care after approval. Drugs demonstrated to have certain outcomes in trials of younger populations may not have similar effectiveness in older adults, and such use may also put patients in underrepresented older age groups at increased risk for unexpected side effects. The current R01 grant (“Understanding effectiveness of new drugs in older adults shortly after market entry”) evaluates a framework for developing more timely and robust insight regarding the effectiveness of new FDA-approved drugs in older adults. This supplemental application augments the R01 grant with bioethics research examining the issues in prescribing drugs for older patients when RCTs leading to FDA approval did not include those patients. We will explore the bioethical implications of the use of drugs in populations different from those recruited into their pivotal RCTs, including the need for enhanced disclosure as part of informed consent procedures and regulatory changes that would make approvals conditional on evidence generated in real- world patient populations. These goals will be pursued by conducting focus groups with older adult patients and semi-structured interviews with prescribers. Based on the results of these research efforts, we will formulate regulatory and clinical practice recommendations to promote patient autonomy and informed decision making.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: 10.2147/clep.s358583
发表时间: 2022
期刊: Clinical epidemiology
影响因子: 3.9
作者: []
通讯作者:
DESIGN DIFFERENCES EXPLAIN VARIATION IN RESULTS BETWEEN RANDOMIZED TRIALS AND THEIR NON-RANDOMIZED EMULATIONS.
设计差异解释了随机试验与其非随机模拟之间结果的差异。
DOI: 10.1101/2023.07.13.23292601
发表时间: 2023
期刊: medRxiv : the preprint server for health sciences
影响因子: --
作者: [Heyard,Rachel, Held,Leonhard, Schneeweiss,Sebastian, Wang,ShirleyV]
通讯作者: Wang,ShirleyV
DOI: 10.1002/pds.5507
发表时间: 2023-01
期刊: Pharmacoepidemiology and drug safety
影响因子: 2.6
作者: []
通讯作者:
DOI: 10.1038/s41467-022-32310-3
发表时间: 2022-08-31
期刊: Nature communications
影响因子: 16.6
作者: []
通讯作者:
共 8 条
    Mathematical and computational modeling of suicidal thoughts and behaviors
    • 批准号:
      10437592
    • 项目类别:
    • 资助金额:
      $3.28万
    • 财政年份:
      2021
    • 负责人:
      Shirley Wang
    • 依托单位:
    Generalizing data from randomized trials to predict long-term treatment outcomes in older populations
    • 批准号:
      10434650
    • 项目类别:
    • 资助金额:
      $46.33万
    • 财政年份:
      2018
    • 负责人:
      Shirley Wang
    • 依托单位:
    Understanding effectiveness of new drugs in older adults shortly after market entry
    • 批准号:
      9908033
    • 项目类别:
    • 资助金额:
      $36.41万
    • 财政年份:
      2018
    • 负责人:
      Shirley Wang
    • 依托单位:
    Understanding effectiveness of new drugs in older adults shortly after market entry
    • 批准号:
      10133498
    • 项目类别:
    • 资助金额:
      $36.56万
    • 财政年份:
      2018
    • 负责人:
      Shirley Wang
    • 依托单位:
    海外基金